OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Oxford Biomedica PLC
30 June 2005


Oxford BioMedica plc (the 'Company')

Notification of Major Interests in Shares

The Company has received notification from Calyon Corporate and Investment Bank
that on 29 June 2005 Credit Agricole Cheuvreux International Ltd had an interest
in 36,917,000 Oxford BioMedica plc 1p ordinary shares. This represents 9.82% of
the presently issued share capital of the Company, which stands at 375,841,175
shares.

good start for the week

This will be the reason why:

Oxford Biomedica gets 2 new lentivirus patents in China
AFX


LONDON (AFX) - Gene therapy group Oxford Biomedica PLC said it was granted two patents by the Patent Office of the Peoples' Republic of China that have broad claims covering vectors derived from lentiviruses.

These are the first patents covering the commercial use of the company's LentiVector technology in China, it said, adding that China is the only

country in the world with an approved gene therapy product.

The LentiVector technology forms the delivery system for the Oxford Biomedica's neurotherapy pipeline, including products for Parkinson's disease, age-related macular degeneration, motor neuron disease, spinal muscular atrophy and nerve repair.

Patents in China might be more valuable then elswhere with the large growth rate in China.

It will be interesting to see what plans OXB has for deals in China.

The upward trend to 40+ will continue now, large investors (well all shareholders really) will be waiting for that ever more critical update on Trovax and any further partnerships or deals for Lentivector technology will help momentum, this share could quite easily be 1 by the end of yr, the immediate downside is limited as many large institutions now have it on their radars.

There's an interesting new thread called BIOS which includes progress of OXB. There's more and more serious interest in this stock as all their milestones are reached and the race shortens for that cancer cure blockbuster. Expect a much Higher profile for this Company over the coming months which will propell the sp upwards. Once the 40p level has been breached twice, 50p is attainable shortly afterwards and Newsflow will keep the sp up.

1 million share Purchase this morning, encouraging!!

Feel more confident to hold onto my shares seeing that 1m purchase. Hard to buy in on the dips. Seems each high becomes the next low sustained level. IMO

Sorry doubled post

Oxford Biomedica PLC
25 July 2005


FOR IMMEDIATE RELEASE 25 JULY 2005

OXFORD BIOMEDICA IS AWARDED GRANT FOR MONUDIN(R) FROM THE MOTOR NEURONE DISEASE
ASSOCIATION

Oxford, UK: 25 July 2005 - Oxford BioMedica (LSE: OXB), the leading gene therapy
company, announced today that the UK Motor Neurone Disease (MND) Association has
awarded a research grant to support preclinical evaluation of MoNuDin for the
treatment of Amyotrophic Lateral Sclerosis (ALS), the most common form of motor
neurone disease. The grant is initially for 350,000, which will fund a key
preclinical efficacy study and support preparations for clinical trials. The
Company is targeting the start of clinical development in 2006-07.

MoNuDin is a novel gene therapy product, which delivers a vascular endothelial
growth factor (VEGF) gene, a neuroprotective factor, using the Company's
proprietary LentiVector system. A previous preclinical study of MoNuDin showed
that both onset and progression of disease was slowed and that life expectancy
was extended by 30%, representing one of the most effective therapies reported
in the field to date. These results were published in May 2004 in Nature
magazine (Volume: 429, Issue: 6990 pp: 413-417).

Oxford BioMedica has previously secured financial support for MoNuDin from the
US ALS Association. The MND Association and other US and UK charitable
organisations are considering further sponsorship that could fund initial
clinical trials of MoNuDin in ALS patients. ALS causes adult-onset, progressive
motor neuron degeneration in the brain and spinal cord, resulting in paralysis
and death three to five years after onset in most patients. There is currently
no known cure for motor neurone disease, a condition that affects approximately
100,000 people in Europe and the USA.

Commenting on the grant from the MND Association, Oxford BioMedica's Chief
Executive, Professor Alan Kingsman said: 'We are very pleased to have received
sponsorship from another leading charity. This grant from the MND Association
provides further endorsement of MoNuDin's potential as a treatment of ALS, for
which there is currently no effective therapy. There is considerable interest in
this programme from charities and other organisations, which could lead to
additional financial support'.

-Ends-

Very good news and the " representing one of the most effective therapies reported
in the field to date." part interests me. I expect more news on the lentivector programme over the next couple of mths and coupled with a statement on Trovax could really boost the sp. Takeover possibility has not been erased either, so i am still predicting this as share of the year..and next!

i have had oxb for about 3 years so far and have not seen any bad news for it. they have several good products in the pipeline and keep on making steady progress. Trovax is coming towards its final stages of development soon (ish) and it will be nice to see how this effects the company.

chart is looking good; any experts to say what the next level of resistance is?

I would be very wary of applying any meaningful form of TA to this share. Historically 45p appears the next medium-term resistance level but I have found that any form of TA that spans more than 2yrs worth of data is highly suspect.

1 share sold at 2.00pm today. What`s the logic there ?

maybe it's a golden share :)

Seems there is every chance of reaching 40p to-day (given the buys v sells ratio)
but for some reason SP is stuck and resisting - any views ??

More Super news for OXB and knowing that there is always a delayed reaction to news boosting the sp, should easily pass through 40p this week. This news means that OXB has an excellent portfolio of drugs/treatments/drug delivery systems that puts it at the forefront of the new age Gene technolgy that will see future cures of many diseases. "LONDON (AFX) - Gene therapy company Oxford Biomedica PLC said the first stage of its Phase II trials for the pancreatic cancer treatment MetXia has been successfully completed, with 'encouraging' results, and that it is now recruiting patients for the second stage of trials.

MetXia comprises a highly engineered retrovirus that delivers the P450 gene, which acts like the naturally occurring enzyme P450 in activating the chemotherapy drug cyclosphosphamide (CPA) in the body, to tumour cells.

MetXia and CPA are being evaluated for use by patients undergoing palliative surgery for pancreatic cancer.

Oxford BioMedica chief executive Alan Kingsman said: 'It is very encouraging that MetXia has achieved its endpoints of safety and gene transfer with this novel route of delivery.'

'We look forward to evaluating clinical benefit in the next stage of the trial. There is a clear unmet need for effective therapies for pancreatic cancer, which MetXia has the potential to address. '

FT.com
Oxford Biomedica rose 2.2 per cent to 35p amid speculation the gene therapy group was close to agreeing a deal with Pfizer to develop TroVax, a colon cancer treatment. Oxford, which already has a licencing agreement with Pfizer for its lentivirus-based gene technology, could announce a deal in the next few weeks.

Thank's Barry. They kept that quiet, no announcements yet. This, I believe is the most significant piece of news to come so far! and really endorses Trovax. Watch these, they will rocket before long, patience is about to be rewarded.